A narrative review on tirzepatide's therapeutic potential in glycemic control and cardioprotection.

This amounted to a 50–60% reduction in AHI with tirzepatide versus minimal change with placebo, a highly significant improvement ( P < 0.001) [ 9 ] .

also in 93,232 other papers

However, this result did not reach statistical significance, largely due to the low number of MACE events and relatively short trial durations, which were primarily designed to assess glycemic and weight endpoints rather than cardiovascular outcomes [ 29 ] .

also in 78,910 other papers

These findings suggest a favorable trend, but definitive cardiovascular benefit cannot be concluded until results from dedicated CVOTs, such as SURPASS-CVOT, become available.

also in 1,053 other papers